Dr. Reddy's enters the Dermatology topical anti-fungal market with the launch of ‘Ebernet™’ - (Eberconazole)

September 05, 2007, Hyderabad: Ebernet™ (Eberconazole 1% cream) has been launched nationwide in September, marking the entry of Dr. Reddy’s into the Rs.100 crore topical anti-fungal market, with an innovative, first to launch formulation.

Ebernet™, an innovative formulation with superior penetration properties, is indicated in the treatment of superficial fungal infections and is available in 10gm pack. Ebernet™ is a brand licensed from the original innovator company, Salvat Laboratories of Spain.

Notes to the editor:

• The topical anti-fungal market is about Rs100 crore, growing at the rate of 12%.
  Brief mode of action of Ebernet:
• Eberconazole (nitrate) is an Imidazole derivate that inhibits the synthesis of ergosterol, an essential component of the cytoplasmic membrane
• This leads to an alteration in its structure and function, thereby inhibiting the growth of the fungus.
• Eberconazole has antifungal as well as potent anti-inflammatory effects.
• Leading brands of Dr.Reddy’s in the Dermatology segment are Mintop™, Venusia™ and Ultravex™.

Disclaimer:
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's:
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer.

www.drreddys.com

For more information please contact :

Investors and Financial Analysts:
Nikhil Shah at nikhilshah@drreddys.com or on +91-40-23731946 ext. 308

Media:
M Mythili at mythilim@drreddys.com or on +91-40-66511620.